Compare Incyte Corporation (INCY) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs IAC/Interactivecorp — how do they compare? Incyte Corporation trades at $118.03 (market cap $23.11B), while IAC/Interactivecorp trades at $44.04 (market cap $3.32B). The key difference: Incyte Corporation is far larger — about 7× IAC/Interactivecorp's market cap, and Incyte Corporation is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals.
| INCY | PPLI | |
|---|---|---|
Market Cap | $23.11B | $3.32B |
Sector | Health | Media |
52-Week High | $118.52 | $47.62 |
52-Week Low | $67.38 | $31.52 |
Enterprise Value | $19.13B | $3.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
PPLI trades at $44.71, up 0.4% today, with a bullish technical signal from moving averages and oversold short-term RSI. Recent quarters show earnings misses, but revenue stabilized near $2.4B in 2025. The stock trades below book value (P/B 0.73) and carries a consensus price target of $55.40. News highlights potential MGM acquisition talks and Q2 2026 earnings call scheduled for August 4th.
Outlook is mixed: strong analyst buy ratings (64%) and undervaluation signals support upside, but persistent net losses and volatile cash flows pose risks. Investors should weigh the discount to NAV against execution challenges in achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
